Metagenomics studies for the diagnosis and treatment of prostate cancer. Issue 3 (2nd December 2021)

• Record Type: Journal Article
• Authors: Zarei, Ali; Javid, Hossein; Sanjarian, Sara; Senemar, Sara; Zarei, Hanieh
• Is Part Of: Prostate. Volume 82:Issue 3(2022)
• Page Start: 289
• Page End: 297
• Publication Date: 2021-12-02
• Subjects: metagenomics -- microbiome -- next generation sequencing -- prostate cancer; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.24276
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract: Aim: Mutation occurs in the prostate cell genes, leading to abnormal prostate proliferation and ultimately cancer. Prostate cancer (PC) is one of the most common cancers amongst men, and its prevalence worldwide increases relative to men's age. About 16% of the world's cancers are the result of microbes in the human body. Impaired population balance of symbiosis microbes in the human reproductive system is linked to PC development. Discussion: With the advent of metagenomics science, the genome sequence of the microbiota of the human body has been unveiled. Therefore, it is now possible to identify a higher range of microbiome changes in PC tissue via the Next Generation Technique, which will have positive consequences in personalized medicine. In this review, we intend to question the role of metagenomics studies in the diagnosis and treatment of PC. Conclusion: The microbial imbalance in the men's genital tract might have an effect on prostate health. Based on next‐generation sequencing‐generated data, Proteobacteria, Firmicutes, Actinobacteria, and Bacteriodetes are the nine frequent phyla detected in a PC sample, which might be involved in inducing mutation in the prostate cells that cause cancer.